OCS: Big Insights Ahead at Neuro-Ophthalmology Meeting!

Company Overview: Oculis Holding AG (NASDAQ: OCS) is a Swiss biopharmaceutical company focused on developing innovative ophthalmic and neuro-ophthalmic therapies. Its pipeline includes late-stage candidates like OCS-01 (a high-concentration dexamethasone eye drop for diabetic macular edema and post-surgery inflammation), OCS-02 (licaminlimab, a topical anti-TNF for dry eye disease), and OCS-05 (privosegtor, a first-in-class neuroprotective agent for acute optic neuritis and other neuro-retina conditions) (investors.oculis.com) (investors.oculis.com). Notably, OCS-05 has shown promising Phase 2 results in acute optic neuritis, demonstrating neuroprotective benefits on retinal structure and visual function (investors.oculis.com). The company’s upcoming presence at a neuro-ophthalmology meeting is expected to shed more light on this program – a catalyst closely watched by investors as Oculis advances toward its first potential product approvals. Meanwhile, a review of Oculis’s financial fundamentals – including its dividend policy, capital structure, valuation, and key risks – provides additional insight into the stock’s investment profile.

Dividend Policy, History & Yield

No Dividend to Date: Oculis has never declared or paid any cash dividends on its ordinary shares and does not currently intend to do so for the foreseeable future (www.sec.gov). As an R&D-stage biotech with no approved products or product revenue, the company’s priority is to reinvest any future earnings into advancing its pipeline rather than returning cash to shareholders (www.sec.gov). Management explicitly states that any future earnings, if generated, will be used to fund growth, and investors “are not likely to receive any dividends… for the foreseeable future.” (www.sec.gov) In line with this policy, OCS’s dividend yield stands at 0%, and no dividend payments have been made since its NASDAQ listing in 2023.

AFFO/FFO Not Applicable: Metrics like Funds From Operations (FFO) or Adjusted FFO (AFFO) are generally used for cash-generative companies (e.g. REITs) and are not meaningful for Oculis. The company remains pre-revenue – aside from minor grant income (~CHF 0.9 million in 2023) – and is incurring substantial net losses as it funds clinical trials (investors.oculis.com). In 2024, Oculis reported a net loss of CHF 85.8 million (≈$97.4 million), similar to the prior year’s CHF 88.8 million loss (investors.oculis.com). These ongoing losses underscore that Oculis has no positive operating cash flow or earnings to distribute. As a result, traditional payout metrics and yield analysis are not applicable, and investors in OCS should be prepared for value creation via stock price appreciation rather than dividends (www.sec.gov) (www.sec.gov).

Leverage and Debt Maturities

Balance Sheet Transformation: Oculis emerged as a debt-free company following its March 2023 SPAC merger and PIPE financing. At year-end 2023, the company had no long-term financial debt on its balance sheet, a sharp improvement from the prior year when CHF 122.45 million in long-term debt was carried (largely related to pre-merger financing) (investors.oculis.com). This reduction reflects the conversion of Oculis’s legacy preferred shares and convertible loans into equity upon the Nasdaq listing. Notably, Oculis had Series B and C preferred stock that accrued a 6% annual dividend and were classified as liabilities under IFRS – all of these preferred shares (and accumulated dividends) were converted to common equity as part of the SPAC business combination (www.sec.gov). The elimination of this debt-like preferred equity obligation significantly deleveraged the company and cleaned up its capital structure in 2023.

Current Debt and Maturities: With the preferred liabilities gone, Oculis’s interest-bearing debt is essentially zero. The only non-equity long-term items on the balance sheet are modest lease liabilities and pension obligations (together under CHF 1.2 million) (investors.oculis.com). Oculis does not have traditional loans or bonds outstanding, so there are no significant debt maturities in the near or medium term. This means the company faces no scheduled principal repayments that could strain its cash flows. The capital structure is funded almost entirely by equity, which is common for clinical-stage biotechs. Investors thus don’t need to worry about refinancing or default risk at this stage; instead, Oculis’s financing strategy has been to raise cash through equity offerings as needed to extend its runway.

Recent Capital Raises: Oculis has proactively bolstered its cash position through equity issuances rather than debt. In April 2024, it raised $59 million in gross proceeds via a direct share offering to institutional investors (5 million shares at $11.75) (investors.oculis.com) (investors.oculis.com). More recently, in February 2025, Oculis completed an oversubscribed public equity offering of 5 million shares at $20.00, bringing in about $100 million gross (≈$93 million net) (www.nasdaq.com) (www.nasdaq.com). These financings, along with the SPAC/PIPE cash, have provided substantial liquidity without incurring debt. Oculis’s avoidance of leverage means no interest expense burden and a lower financial risk profile, albeit at the cost of dilution to shareholders (discussed under Red Flags).

Coverage and Liquidity

Interest and Obligation Coverage: Given Oculis’s debt-free status, traditional interest coverage ratios are a non-issue – there are no interest payments to cover. Likewise, dividend coverage is moot since no dividends are paid. The more relevant consideration is Oculis’s ability to cover its operating expenses and R&D burn with available resources. Here, the company appears to be on solid footing in the near term. As of December 31, 2024, Oculis reported $109 million in cash, cash equivalents, and short-term investments on hand (investors.oculis.com). With the addition of roughly $93 million in net proceeds from the early 2025 equity raise, management states it has secured a cash runway into early 2028 (investors.oculis.com). In other words, the company expects to fund its current clinical programs for about three more years without needing additional capital, assuming its budget forecasts hold.

Cash Burn vs. Runway: Oculis’s implied annual cash burn (on the order of ~$90–100 million, based on recent net losses (investors.oculis.com)) is substantial, but the multi-year runway suggests that recent funding will comfortably cover planned Phase 3 trials and operations. By management’s estimates, the existing cash should support the completion of pivotal trials – including the ongoing Phase 3 DIAMOND program for OCS-01 in diabetic macular edema (expected to read out in H1 2026) – and potentially the initial regulatory submission processes (investors.oculis.com). It’s worth noting that this runway projection likely assumes no major scope expansions or new programs beyond the current pipeline. If trials progress on schedule, Oculis might reach key inflection points (such as an NDA filing or partnership deal) before it needs more cash, thereby improving its options for future financing. However, should there be unexpected delays or cost overruns, the company might have to seek additional funding sooner than 2028 – a scenario management recognizes as a risk if financing markets tighten (www.sec.gov).

Working Capital and Coverage Ratios: Oculis’s short-term liquidity appears healthy. Current assets at end of 2024 (over $100 million) comfortably exceeded current liabilities (~$19 million at end of 2023, likely higher by end 2024 after trial accruals) (investors.oculis.com), meaning the company has ample working capital. With essentially no interest expense and minimal fixed financial obligations, Oculis can channel its cash toward R&D and operating needs. In summary, while coverage ratios in the traditional sense aren’t applicable, Oculis’s liquidity position is strong relative to its burn rate, and the company has several years of operational runway secured barring unforeseen circumstances (investors.oculis.com). Investors should still monitor the pace of cash usage versus management’s guidance, as a faster burn (or new initiatives) could shorten the runway.

Valuation

Market Capitalization and P/B: OCS shares have rallied amid clinical progress, giving the company a robust valuation despite zero product revenue to date (www.sec.gov). As of March 2026, Oculis’s market capitalization stands around $1.5 billion (companiesmarketcap.com). At a recent share price near $27–28 (companiesmarketcap.com), this reflects substantial investor optimism about the pipeline’s commercial potential. In concrete terms, OCS trades at a very high multiple of current book value – many times over its ~$100 million tangible equity. For instance, by December 2025 the market cap was roughly €1.02 billion (~$1.1 billion) (companiesmarketcap.com), which is an order of magnitude greater than the company’s net assets (Oculis’s total equity was CHF 93.7 million at 2023 year-end, and remained well under $150 million after 2024 due to continued losses). This price-to-book ratio in the high single or low double-digits underscores that investors are valuing Oculis on its future prospects – anticipated cash flows from successful drugs – rather than on current financials.

Earnings and Cash Flow Multiples: Traditional valuation metrics like P/E or EV/EBITDA are not meaningful for OCS. Oculis’s earnings are negative (trailing 12-month net loss of around $135 million as of early 2026) (www.marketcapwatch.com), and it will likely remain unprofitable until one or more products reach market. With no EBITDA or FFO, the stock’s valuation is essentially based on pipeline-adjusted NPV and comparable biotech multiples. Investors are effectively pricing in the probability-weighted revenue of OCS-01, OCS-02, and OCS-05 in their respective indications. This approach is inherently speculative and sensitive to clinical outcomes. For context, a market cap near $1.5 billion suggests the market anticipates one or more of Oculis’s drugs could achieve eventual annual sales in the high hundreds of millions (assuming biotech valuations of ~3–5× peak sales for late-stage assets).

Peer Comparison: Among ophthalmology-focused biotechs, Oculis’s valuation appears upscale but not unprecedented given its late-stage programs. Companies with Phase 3 ophthalmic drugs (for retina or dry eye) often reach billion-dollar valuations, especially if they address large markets. Oculis’s lead asset, OCS-01, targets diabetic macular edema – a multibillion-dollar market currently dominated by injectable drugs – and OCS-02 addresses dry eye, another large market. By comparison, Apellis Pharmaceuticals (NASDAQ: APLS), which developed a novel eye therapy, commanded multi-billion valuations even before approval, though it had partnerships. Oculis is smaller in scale but similar in that it is attempting first-in-class topical therapies. Its valuation is also supported by high-quality institutional investors (including Novartis’s venture fund, Earlybird, and funds managed by Tekla and others) who invested through the PIPE and follow-on offerings (investors.oculis.com) (www.sec.gov). While direct peer multiples (P/FFO, etc.) aren’t relevant, OCS’s ~$1–1.5 billion market cap places it among the better-capitalized mid-cap biotech cohort, reflecting a mixture of pipeline promise and risk. Any significant clinical news – positive or negative – could cause outsized swings in this valuation since it is not anchored by current earnings.

Key Risks

Clinical and Regulatory Risk: Oculis is a clinical-stage company with no approved products and no revenues, which inherently makes it a high-risk investment (www.sec.gov). The company has not yet completed a Phase 3 trial or obtained any marketing approvals (www.sec.gov). There is no guarantee that its ongoing Phase 3 studies (for OCS-01 in DME and post-surgery inflammation) will meet their endpoints or that regulators will deem the data sufficient for approval. Failure of any pivotal trial – or even delays in development – could substantially impair Oculis’s valuation. Even if trials succeed, the regulatory review process poses uncertainties; additional studies could be required, or unexpected safety issues could arise. As a foreign issuer, Oculis will seek approvals in multiple jurisdictions (U.S., EU, etc.), each with distinct requirements. In short, pipeline success is not assured, and Oculis’s future hinges on clinical milestones that carry binary risk.

Need for Additional Financing: Like most biotechs, Oculis will likely require additional capital to fully commercialize its products and possibly to complete all trials (www.sec.gov). The company projects a cash runway into early 2028 (investors.oculis.com), but this assumes timely progress and no major new initiatives. If development timelines slip or if the company expands its pipeline, funding needs could accelerate. No committed source of capital exists beyond current cash (www.sec.gov) – Oculis has no product revenue or credit line to fall back on. Thus far it has relied on equity markets, which means if market conditions deteriorate or trial results disappoint, raising capital on favorable terms might be challenging. A failure to obtain financing when needed “may render [Oculis] unable to complete the development and, if approved, commercialization” of its therapies (www.sec.gov). This risk is mitigated in the near term by the recent $93 million raise, but it remains a factor for the longer term, especially if launch activities (sales force, manufacturing scale-up) come into play before the company becomes self-sustaining.

Competitive and Market Risks: Oculis faces formidable competition from established players in ophthalmology. Its lead product OCS-01 (topical dexamethasone) will compete in diabetic macular edema against well-entrenched treatments like anti-VEGF injections marketed by Roche/Genentech (Lucentis/Byooviz), Regeneron/Bayer (Eylea), and others (www.sec.gov). These pharma giants have vast resources and existing prescriber relationships. Even in inflammation/pain after eye surgery – a more generic indication – big ophthalmic companies like AbbVie (Allergan), Alcon, Bausch + Lomb, and Teva offer steroid or NSAID eye drops (www.sec.gov). For dry eye disease, OCS-02 would enter a crowded arena with competitors such as AbbVie (Restasis/Refresh), Novartis (Xiidra), and others developing novel therapies (www.sec.gov). There’s also the “status quo” risk that physicians may be slow to adopt new treatments; for example, mild DME is often just observed rather than treated aggressively (www.sec.gov). Pricing and reimbursement pose additional uncertainties – payers might favor cheaper existing therapies or require proof of substantial improvement. In summary, even if Oculis’s drugs reach market, they must prove competitive on efficacy, safety, convenience, and cost to capture share from much larger companies.

Regulatory and Partnership Dependencies: Part of Oculis’s pipeline strength comes from in-licensed assets, which introduces dependency risks. OCS-02 was licensed from Novartis, and OCS-05 from Accure Therapeutics (www.sec.gov). The license agreements impose development and payment obligations; for example, Oculis must pay significant milestones and royalties to Novartis on OCS-02’s success (up to CHF 81.6 million in milestone payments, plus royalties) (www.sec.gov). If Oculis fails to meet diligence requirements or payment terms, the licensors could potentially terminate the agreements (www.sec.gov), jeopardizing those programs. Even aside from worst-case termination, the future royalty streams to Novartis/Accure will reduce Oculis’s net margins on those products if they do succeed. Additionally, Oculis’s strategy may involve seeking partners for commercialization in certain markets – if it cannot secure partnerships on acceptable terms, it might struggle to commercialize globally. Regulatory risk is also heightened by the fact that Oculis will need to navigate multiple regulatory regimes (FDA, EMA, etc.) and possibly companion diagnostic approval for OCS-02’s precision medicine approach in dry eye (to identify responders), adding complexity to an already challenging path.

Key Person and Operational Risks: As a smaller company, Oculis’s success depends on retaining its specialized team and advisors. It has added seasoned ophthalmology experts to its board and advisory committees (www.nasdaq.com) (investors.oculis.com), but competition for talent in biotech is intense. Any significant turnover in management or delays in scaling up operational capabilities (e.g. manufacturing of eye drops at commercial scale) could create bottlenecks. Finally, currency risk is a minor factor – Oculis reports in Swiss Francs and operates in Switzerland and the US, so exchange rate fluctuations (CHF/USD/EUR) can impact reported results (www.sec.gov), though this is overshadowed by bigger strategic risks.

Red Flags for Investors

While Oculis’s progress is encouraging, a few red flags and cautionary signs warrant attention:

– Dilution of Shareholders: Oculis has significantly increased its share count through financing activities in the past two years. At the time of the SPAC merger in March 2023, roughly 36.65 million ordinary shares were outstanding (www.sec.gov). By early 2025, the share count rose to about 46–47 million after the April 2024 and Feb 2025 equity issuances. Furthermore, public and private warrants from the SPAC (exercise price $11.50) have been in-the-money and could add ~4.25 million shares upon exercise (www.sec.gov) (www.sec.gov). Indeed, recent data show 52.3 million shares outstanding (likely reflecting warrant exercises and stock-based compensation) (www.marketcapwatch.com). This amounts to roughly a 43% increase in outstanding shares since listing. While raising capital is necessary for a pre-revenue biotech, such dilution can erode per-share value for existing shareholders (www.nasdaq.com). Investors should be mindful that further dilution remains possible if Oculis taps equity markets again before achieving self-sustaining revenue.

– Contingent Liabilities & Royalties: As mentioned, Oculis’s in-licensed programs carry hefty contingent payment obligations. The Novartis license for OCS-02 could require CHF 81.6 million (~$97 million) in milestone payouts as the drug hits development and commercialization milestones (www.sec.gov). OCS-05’s license from Accure likely entails its own milestone fees (though undisclosed, similar deals can also run in the tens of millions). Additionally, both programs would incur royalties on sales (low-single-digit for OCS-02 on top of any Novartis third-party royalties) (www.sec.gov). These obligations mean that if Oculis’s products succeed, the company will not retain the full economics – a portion of future revenues is pre-committed to licensors. While not an immediate cash drain (no payments are due unless success is achieved), these liabilities could reduce eventual profit margins and make Oculis less attractive to acquirers or investors who prefer wholly owned assets.

– Lack of Revenue Diversification: Until at least one product is approved, Oculis remains entirely dependent on external funding. The company’s grant income (~$0.9M/year) is minimal (investors.oculis.com), and there are no other revenue streams (no licensing-out deals or services). This singular reliance on pipeline progress means any setback can significantly impact the company’s viability. In contrast, some peers might have royalty income or approved niche products that provide a baseline revenue – Oculis does not. The absence of any interim revenue (for example, no expanded access sales or regional licensing deals yet) is a typical red flag in early biotechs; it emphasizes that all eggs are in the R&D basket.

– SPAC Legacy and Lock-Up Expirations: Oculis went public via a SPAC merger (with European Biotech Acquisition Corp.), a route that has sometimes been associated with volatile post-merger trading. Thanks to an upsized PIPE, the initial funding was solid (investors.oculis.com), but one should note if any lock-up agreements for insiders or PIPE investors have expired or are nearing expiration. Large shareholders (founders, SPAC sponsors, or PIPE funds) could choose to sell shares as lock-ups release, which might put downward pressure on the stock price. The presence of reputable biotech funds in Oculis’s investor list suggests they may be longer-term holders, but this is an area to monitor in terms of stock float and potential insider selling.

– High R&D Burn Rate: Oculis’s annual net loss of ~$97–99 million (investors.oculis.com) points to a high cash burn relative to its size. While the company has cash reserves now, the elevated burn rate is a caution. It reflects multiple concurrent Phase 3 programs – a sign of ambition – but also means Oculis must execute efficiently on trials to avoid cost overruns. Any unexpected expenses (e.g. needing an extra study arm, manufacturing scaling issues, or new trials for safety) could further increase the burn. A high burn rate also ties into financing risk; if, for instance, trial timelines extend, Oculis might deplete its cash faster than anticipated. Investors should watch R&D expense trends in quarterly updates to ensure the burn is in line with the runway guidance.

– Operational Complexity: Another subtle flag is that Oculis is running several late-stage trials in parallel across different indications (retina, anterior segment, neuro-ophthalmology). This is logistically complex for a relatively small company. Managing global Phase 3 trials (some likely in the US, EU, and elsewhere) tests the organization’s bandwidth. There’s a risk that being stretched across programs could impact the speed or quality of execution in one or more trials. Thus far, Oculis has hit its enrollment and data release targets, but as Phase 3 programs progress (especially the large DIAMOND trials in DME), operational strain could emerge. Any delays in trial enrollment or data analysis would be a red flag pointing to resource constraints.

In summary, none of these red flags are insurmountable – they are common in biotech – but they highlight why OCS remains a high-risk, high-reward stock. Prudent investors will keep an eye on dilution, cash burn, and Oculis’s ability to navigate its contractual obligations and multi-trial workload.

Open Questions and Outlook

Timeline to First Approval: A key question is when Oculis might achieve its first product approval and revenue. The company’s most advanced program is OCS-01. It has completed one Phase 3 trial in post-cataract surgery inflammation (OPTIMIZE-1, positive results) (www.ophthalmologytimes.com) and initiated a second confirmatory trial (OPTIMIZE-2) (eyewire.news). If OPTIMIZE-2 reads out positively in 2025, Oculis could potentially file its first New Drug Application (NDA) for OCS-01 (for post-surgical use) as early as late 2025 or 2026. Meanwhile, the larger opportunity – OCS-01 for diabetic macular edema – requires two Phase 3 trials (the DIAMOND program). Those trials are on track to complete enrollment in 2025, with top-line data expected in H1 2026 (investors.oculis.com). An open question is whether positive DME results could accelerate a partnering or buyout scenario (given the retinal market magnitude), or if Oculis will proceed to file for approval on its own in 2026–27. Investors will be watching mid-2026 closely: the DME data announcement is a major inflection point that could dramatically impact Oculis’s trajectory, for better or worse.

Commercialization Strategy – Partner or Solo?: Oculis’s plans for commercializing its therapies remain to be clarified. Will the company build its own salesforce (for example, a specialized ophthalmology sales team for eye drops), or seek a partnership with Big Pharma? The decision may differ by product – for instance, a large primary-care type market like dry eye (OCS-02) might benefit from a partner with an established commercial infrastructure, whereas a specialty retina product could be launched by a focused in-house team calling on retinal specialists. The presence of Novartis as both a licensing partner and investor raises the question of whether Novartis (a major ophthalmology player) might be a natural commercialization partner or even an acquirer if OCS-02 or OCS-01 prove out. Thus far, Oculis has not announced any co-development or co-marketing partnerships for its lead products, keeping its options open. This strategic question – go it alone or team up – will need answering as the company approaches the regulatory filing stage. The competitive landscape makes a strong case for partnering: Oculis’s potential rivals (Regeneron, Roche, AbbVie, Novartis, etc.) have deep marketing resources (www.sec.gov) (www.sec.gov). A partnership could accelerate market penetration, but it would also mean sharing economics. Investors will want to see a clear plan from management on how they intend to maximize product reach without overextending the company’s resources.

Pricing and Market Adoption: Another open question is how Oculis will price its therapies and drive market uptake if approved. For OCS-01 in DME, will payers embrace an eye-drop alternative to injections? The value proposition is improved patient comfort and possibly earlier intervention, but Oculis will need to demonstrate cost-effectiveness (especially if the clinical efficacy is modest relative to injections). If priced too high, insurers might favor existing treatments; if priced too low, Oculis’s revenue could be limited. In dry eye, OCS-02 would enter a crowded market – its success may hinge on a precision medicine angle (identifying responder patients via a biomarker). It remains to be seen if Oculis can develop a companion diagnostic or selection criteria to target OCS-02 to those most likely to benefit (www.sec.gov). The “precision” approach could differentiate OCS-02, but also adds complexity in convincing doctors and payers. These factors – pricing strategy, biomarker development, and education of physicians – are open questions that will shape the commercial success of Oculis’s pipeline beyond just clinical approval.

Will OCS-05 Expand Its Scope? The excitement around OCS-05 (the neuroprotective candidate) at the neuro-ophthalmology meeting raises the question of its future indications. OCS-05 showed positive Phase 2 results in acute optic neuritis (AON) (investors.oculis.com), a rare condition often associated with multiple sclerosis. Acute optic neuritis itself is a niche market – typically steroid treatment is standard, and no neuroprotective therapy exists, so OCS-05 could fulfill an unmet need. However, Oculis has hinted that OCS-05 might have broader applications “in neuro-retina diseases, such as AON and glaucoma.” (investors.oculis.com) Glaucoma is a chronic disease with a large patient population – if OCS-05 can slow optic nerve damage in glaucoma (beyond what intraocular pressure control achieves), it would be a blockbuster opportunity. The open question is: will Oculis pursue OCS-05 in glaucoma or other chronic neurodegenerative eye conditions? Doing so would require additional trials and time, but could vastly expand the drug’s value. It’s possible Oculis might seek a partner or grant funding to explore these extensions. For now, investors await details on OCS-05’s Phase 3 strategy for optic neuritis (Will Oculis run it alone? Will they get orphan drug support?) and any indications of plans “beyond” AON – a topic likely to be discussed at the R&D day and neuro-ophthalmology forums.

Long-Term Vision for the Company: Lastly, there’s an overarching question of Oculis’s endgame: is the aim to become a fully integrated ophthalmology company – taking multiple products through approval and building a commercial portfolio – or to prove its concepts and then be acquired by a larger pharmaceutical company? Many mid-stage biotechs ultimately sell to big pharma if their Phase 3 data is compelling. Oculis’s strong institutional backing and partnerships (e.g., licensing from Novartis, funding from Tekla and others) suggest it could be on the radar of big players (investors.oculis.com) (www.sec.gov). The next 12–18 months will be critical in answering these questions. Phase 3 results, NDA filings, and possibly early launch preparations will clarify whether Oculis remains independent. An acquisition offer is always a wildcard – positive Phase 3 data in DME or a breakthrough in neuro-ophthalmology could trigger interest from pharma companies seeking to bolster their ophthalmic pipelines.

In conclusion, Oculis (OCS) presents a compelling story at the intersection of eye care and neuro-innovation, with multiple shots on goal in large indications. The upcoming neuro-ophthalmology meeting is expected to provide “big insights” into OCS-05’s potential, while milestone events in diabetic eye disease and dry eye are on the horizon (investors.oculis.com) (investors.oculis.com). For investors, OCS offers significant upside if its therapies succeed, but not without considerable risk. The company’s no-dividend, equity-funded model means faith is placed in pipeline execution and future cash flows rather than near-term financial return (www.sec.gov). With a strong cash position and no debt, Oculis is well-positioned to ride out its development plan in the next couple of years (investors.oculis.com). However, clinical results and strategic choices will ultimately determine whether today’s ~$1.5 billion valuation is justified or needs revision. Open questions remain regarding commercialization and long-term strategy, but each planned data readout brings Oculis closer to providing answers. Investors should stay tuned to forthcoming updates – both in scientific forums and financial disclosures – as 2026 looks to be a defining year for OCS and its ambitious goal to “save sight” in novel ways (investors.oculis.com).

Sources:

1. Oculis Holding AG – Nasdaq Listing Announcement, Pipeline Overview (investors.oculis.com) (investors.oculis.com) 2. Oculis 2023 Annual Report (Form 20-F) – Dividend Policy and Corporate Governance (www.sec.gov) (www.sec.gov) 3. Oculis Q4 2023 and Q4 2024 Financial Results – Balance Sheet, Cash Position, and Net Loss (investors.oculis.com) (investors.oculis.com) 4. Oculis Press Release (Apr 2024) – $59 M Direct Offering and Dual Listing in Iceland (investors.oculis.com) (investors.oculis.com) 5. Nasdaq/GlobeNewswire (Feb 2025) – $100 M Equity Offering Summary (Quiver Quant) (www.nasdaq.com) (www.nasdaq.com) 6. CompaniesMarketCap.com – OCS Market Capitalization and Share Count (Mar 2026) (companiesmarketcap.com) (www.marketcapwatch.com) 7. Oculis 20-F Risk Factors – Need for Additional Financing & Lack of Approved Products (www.sec.gov) (www.sec.gov) 8. Oculis 20-F Risk Factors – Competition and License Obligations (www.sec.gov) (www.sec.gov) 9. Oculis Investor Presentation / Press – OCS-05 Neuroprotective Positioning (investors.oculis.com) 10. Oculis Press Release (Mar 2025) – Cash Runway into 2028 and Upcoming Milestones (investors.oculis.com) (investors.oculis.com)

For informational purposes only; not investment advice.